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Background
Phase III clinical trials are generally large and expensive,
so stopping early for futility is a potentially attractive
approach. It could avoid using further patients and
funds on an ineffective intervention. We aimed to see
how well futility performs for clinical trials in practice.
Materials and methods
We retrospectively applied a futility method to ten can-
cer trials, in which the final hazard ratios (HR) showed
a large, moderate, or no treatment benefit. The target
sample size was reached in all. The conditional power
(CP) is the probability of obtaining a HR of a specified
magnitude, which is statistically significant. Futility ana-
lyses were applied after 25, 50 and 75% of patients were
recruited, or events observed. Two methods were used,
assuming future data are consistent with either (i) the
target HR, or (ii) the observed interim HR. Low CP sug-
gests futility.
Results
Futility analyses could stop some trials with no overall
benefit, but not all, depending on the method used and
timepoint. For example, after observing 50% of the tar-
get number of events, and assuming that future data is
consistent with observed data, 4 out of 5 trials with no
benefit could be stopped early (CP≤9%). Among 3 (of
these 4) studies, trial duration could be reduced by 4-40
months, saving £44k-£385k. The other trial would have
already finished accrual and hence no savings made. Of
concern is that all 4 trials with moderate treatment
effects could have stopped early at some point. For
example, assuming that future data is consistent with
the observed data, these trials could have stopped after
25% of patient accrual (CP≤9%). However, the final HRs
for all four trials showed clinically worthwhile benefits.
Conclusions
Appropriate application of futility methods can substan-
tially shorten trial duration and reduce costs for trials
which ultimately show no benefit. However, studies with
moderate treatment effects could be stopped early,
whilst some studies with no effect may not have been
detected as such. Futility needs to be applied with great
care to avoid missing a worthwhile treatment. We sug-
gest several criteria for stopping a trial early: low CP (e.
g. ≤15%); sufficient number of events; remaining patient
accrual is likely to take several months; and lack of evi-
dence of a benefit for important secondary endpoints
and pre-defined subgroups.
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